← Leaderboards
Jeffrey E Settleman
Massachusetts General Hospital
$9,528,639
Attributed
$10,851,496
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$10,851,496 · 8
By mechanism
R01$8,125,492 · 4
RC2$1,984,285 · 1
P50$618,707 · 1
R03$120,012 · 1
R13$3,000 · 1
Top collaborators
- Nathanael Schiander Gray2 shared
- Timothy J Mitchison2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Anurag Singh$978,460
- Daniel A. Haber$29,412,047
Others in their field
Top investigators on “Guanosinetriphosphatases”
- Gary M Bokoch · Scripps Research Institute$5,663,101
- Philip D Stahl · Washington University$4,129,419
- James Alfred Hoch · Scripps Research Institute$3,883,492
- William Edward Balch · Scripps Research Institute, The$3,327,688
- Vadim Y Arshavsky · Massachusetts Eye And Ear Infirmary$3,252,910
- Richard A. Cerione · Cornell University$3,125,794
Research focus
GuanosinetriphosphatasesProtein Structure FunctionTissue /Cell CultureBiological Signal TransductionEnzyme ActivityPharmaceutical PreparationsPhosphorylationPhosphotransferasesDrosophilidaeLaboratory MouseInsightBiochemicalOncogenicPathway InteractionsBaseCellsSignal TransductionProteinsMutationResponseTumorCancer Cell LineOncogenesGuanosinetriphosphatase Activating Protein
Grant awards (29)
Mechanistic Signatures of Drug Responses in Cancer$984,353
RC2 · FY2010 · HG
Mechanistic Signatures of Drug Responses in Cancer$999,932
RC2 · FY2009 · HG
Gefitinib-sensitive EGF receptor mutants in lung cancer$643,108
R01 · FY2009 · CA · contact PI
Targeting erlotinib-resistant lung cancer with rational combination treatments$340,249
P50 · FY2009 · CA · contact PI
Gefitinib-sensitive EGF receptor mutants in lung cancer$624,020
R01 · FY2008 · CA · contact PI
Specific Biochemical Inactivation of Oncogenic Ras$303,229
R01 · FY2008 · CA · contact PI
Targeting erlotinib-resistant lung cancer with rational combination treatments$278,458
P50 · FY2008 · CA · contact PI
Gefitinib-sensitive EGF receptor mutants in lung cancer$622,316
R01 · FY2007 · CA · contact PI
Specific Biochemical Inactivation of Oncogenic Ras$303,229
R01 · FY2007 · CA · contact PI
Gefitinib-sensitive EGF receptor mutants in lung cancer$536,728
R01 · FY2006 · CA · contact PI
Regulation and Functin of the p190 RhoGAPs$354,904
R01 · FY2006 · CA · contact PI
Specific Biochemical Inactivation of Oncogenic Ras$312,285
R01 · FY2006 · CA · contact PI
Regulation of p190 RhoGAP activity by phospholipids$39,372
R03 · FY2006 · TW · contact PI
Gefitinib-sensitive EGF receptor mutants in lung cancer$552,711
R01 · FY2005 · CA
Regulation and Functin of the p190 RhoGAPs$363,445
R01 · FY2005 · CA
Specific Biochemical Inactivation of Oncogenic Ras$319,800
R01 · FY2005 · CA
Regulation of p190 RhoGAP activity by phospholipids$40,320
R03 · FY2005 · TW
Regulation and Functin of the p190 RhoGAPs$363,445
R01 · FY2004 · CA
Specific Biochemical Inactivation of Oncogenic Ras$318,898
R01 · FY2004 · CA
Regulation of p190 RhoGAP activity by phospholipids$40,320
R03 · FY2004 · TW
FASEB Summer Research Conference on Small G-Proteins$3,000
R13 · FY2004 · CA
Regulation and Functin of the p190 RhoGAPs$363,445
R01 · FY2003 · CA
RHO GTPASE SIGNALING IN EMBRYO MORPHOGENESIS$304,143
R01 · FY2003 · GM
Regulation and Functin of the p190 RhoGAPs$363,445
R01 · FY2002 · CA
RHO GTPASE SIGNALING IN EMBRYO MORPHOGENESIS$295,285
R01 · FY2002 · GM
INTERACTION OF RAS AND RHO SIGNAL TRANSDUCTION PATHWAYS$368,262
R01 · FY2001 · CA
RHO GTPASE SIGNALING IN EMBRYO MORPHOGENESIS$286,683
R01 · FY2001 · GM
INTERACTION OF RAS AND RHO SIGNAL TRANSDUCTION PATHWAYS$357,536
R01 · FY2000 · CA
RHO GTPASE SIGNALING IN EMBRYO MORPHOGENESIS$168,575
R01 · FY2000 · GM